Zobrazeno 1 - 10
of 65
pro vyhledávání: '"multiple ascending dose"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Janine Kutzsche, Dagmar Jürgens, Antje Willuweit, Knut Adermann, Carola Fuchs, Stefanie Simons, Manfred Windisch, Michael Hümpel, Wolfgang Rossberg, Michael Wolzt, Dieter Willbold
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction PRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease. Methods Two placebo‐controlled clinical phase I trials with o
Externí odkaz:
https://doaj.org/article/7342037c03cf4831957e00b00ae4b53c
Autor:
Ryuzo Hanada
Publikováno v:
Clinical Pharmacology in Drug Development
Preclinical data of TAS‐303 (4‐piperidinyl 2,2‐diphenyl‐2‐[propoxy‐1,1,2,2,3,3,3‐d7] acetate hydrochloride), a noradrenaline reuptake inhibitor, show that it increases urethral contraction in rats and may therefore benefit stress urinar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0acea60d686c9bf229f152c3380aec
http://europepmc.org/articles/PMC7687182
http://europepmc.org/articles/PMC7687182
Autor:
Christine Huynh, Janneke M. Brussee, Henriette E. Meyer zu Schwabedissen, Marlene Fonseca, Jasper Dingemanse, Laetitia Pouzol, Patricia N. Sidharta
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss, Pp 112363-(2021)
Antagonism of the chemokine receptor CXCR7 has shown promising effects in diverse disease areas through modulation of its ligands, CXCL11 and CXCL12. Preclinical data of the first-in-class CXCR7 antagonist, ACT-1004-1239, showed efficacy in animal mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4c49853ca6e5f9f612eca42df4b2dd
http://www.sciencedirect.com/science/article/pii/S0753332221011471
http://www.sciencedirect.com/science/article/pii/S0753332221011471
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Pulmonary Circulation
Pulmonary Circulation
Ralinepag (APD811), an oral, potent, and selective prostacyclin receptor (IP) agonist is being developed for treatment of pulmonary arterial hypertension. Two, single-center, randomized, double-blind, placebo-controlled, Phase 1 studies (single ascen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da74a7d74c84902a1a203cf37651ebb
https://doaj.org/article/a1adcb43f1e74081884a9de6dd573d86
https://doaj.org/article/a1adcb43f1e74081884a9de6dd573d86
Autor:
Susan M. Catalano, Hank Safferstein, Michael Grundman, Roger Morgan, Julie Pribyl, Kelsie Mozzoni, Steven T. DeKosky, Jason D. Lickliter, Michelle Higgin, Lon S. Schneider, Robert Guttendorf, Nicholas J. Izzo
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Background Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of Aβ oligomers to neurons. By stopping a key initiating event in Alzheimer's disease, this first-in–class drug candida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62cf8079e5cf92f7fa5c76ca49864bc5
https://doi.org/10.1016/j.trci.2018.11.001
https://doi.org/10.1016/j.trci.2018.11.001
Autor:
Shweta Urva, Julie S. Moyers, Krister Bokvist, Kyle W. Sloop, Jorge Alsina-Fernandez, William C. Roell, Charles Benson, Uma Kuchibhotla, David A. D'Alessio, Corina Loghin, Xuewei Cui, Tamer Coskun, Over Cabrera, Daniel A. Briere, Ruth E. Gimeno, Axel Haupt
Publikováno v:
Molecular Metabolism
Molecular Metabolism, Vol 18, Iss, Pp 3-14 (2018)
Molecular Metabolism, Vol 18, Iss, Pp 3-14 (2018)
Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ca485dc3a86e98e8a5c2fbb364cd27
http://europepmc.org/articles/PMC6308032
http://europepmc.org/articles/PMC6308032
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Erica Winter, Sameeh Salama, Akiko Kano, Navita L. Mallalieu, Ignacio Rodriguez, Anna Maria Geretti, Darren Bentley, Gemma Attley, Katie Patel, Scott Fettner, Elke Zwanziger
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial agents and chemotherapy
Antimicrobial agents and chemotherapy
Nacubactam is a novel β-lactamase inhibitor with dual mechanisms of action as an inhibitor of serine β-lactamases (classes A and C and some class D) and an inhibitor of penicillin binding protein 2 in Enterobacteriaceae. The safety, tolerability, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c47a478020ee10c2944a8f3b0446c220
https://pubmed.ncbi.nlm.nih.gov/32041717
https://pubmed.ncbi.nlm.nih.gov/32041717